A mouse model for MERS coronavirus-induced acute respiratory distress syndrome

Nature Microbiology

Volumn 2, Issue , 2016, Pages

  Cockrell, Adam S ^a   Yount, Boyd L ^a   Scobey, Trevor ^a   Jensen, Kara ^a   Douglas, Madeline ^a   Beall, Anne ^a   Tang, Xian Chun ^b   Marasco, Wayne A ^b   Heise, Mark T ^c   Baric, Ralph S ^a,c  

^a IL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DPP4 PROTEIN, MOUSE; MUTANT PROTEIN; VIRUS RECEPTOR;

ADULT RESPIRATORY DISTRESS SYNDROME; ANIMAL; COMPLICATION; CORONAVIRUS INFECTION; DISEASE MODEL; GENE EDITING; GENETIC RECOMBINATION; GENETICS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MOUSE; PATHOLOGY; TRANSGENIC ORGANISM;

ANIMALS; CORONAVIRUS INFECTIONS; DIPEPTIDYL PEPTIDASE 4; DISEASE MODELS, ANIMAL; GENE EDITING; MICE; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MUTANT PROTEINS; ORGANISMS, GENETICALLY MODIFIED; RECEPTORS, VIRUS; RECOMBINATION, GENETIC; RESPIRATORY DISTRESS SYNDROME, ADULT;

EID: 84999652028     PISSN: None     EISSN: 20585276     Source Type: Journal    
DOI: 10.1038/nmicrobiol.2016.226     Document Type: Article

References (37)

1. Chan, J. F.-W. et al. Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J. Infect. Dis. 212, 1904-1913 (2015).
2. de Wit, E. et al. Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. Proc. Natl Acad. Sci. USA 110, 16598-16603 (2013).
3. Falzarano, D. et al. Infection with MERS-CoV causes lethal pneumonia in the common marmoset. PLoS Pathogens 10, e1004250 (2014).
4. Munster, V. J., de Wit, E. & Feldmann, H. Pneumonia from human coronavirus in a macaque model. N. Engl. J. Med. 368, 1560-1562 (2013).
5. Johnson, R. F. et al. 3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERSCoV Jordan-n3/2012. Virology 490, 49-58 (2016).
6. Johnson, R. F. et al. Intratracheal exposure of common marmosets to MERSCoV Jordan-n3/2012 or MERS-CoV EMC/2012 isolates does not result in lethal disease. Virology 485, 422-430 (2015).
7. Cockrell, A. S. et al. Mouse dipeptidyl peptidase 4 is not a functional receptor for Middle East respiratory syndrome coronavirus infection. J. Virol. 88, 5195-5199 (2014).
8. Coleman, C. M., Matthews, K. L., Goicochea, L. & Frieman, M. B.Wild-type and innate immune-deficient mice are not susceptible to the Middle East respiratory syndrome coronavirus. J. Gen. Virol. 95, 408-412 (2014).
9. de Wit, E. et al. The Middle East respiratory syndrome coronavirus (MERSCoV) does not replicate in Syrian hamsters. PLoS ONE 8, e69127 (2013).
10. Raj, V. S. et al. Adenosine deaminase acts as a natural antagonist for dipeptidyl peptidase 4-mediated entry of the Middle East respiratory syndrome coronavirus. J. Virol. 88, 1834-1838 (2014).
11. Ohnuma, K., Dang, N. H. & Morimoto, C. Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function. Trends Immunol. 29, 295-301 (2008).
12. Agrawal, A. S. et al. Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease. J. Virol. 89, 3659-3670 (2015).
13. Li, K. et al. Middle East respiratory syndrome coronavirus causes multiple organ damage and lethal disease in mice transgenic for human dipeptidyl peptidase 4. J. Infect. Dis. 213, 712-722 (2016).
14. Zhao, G. et al. Multi-organ damage in human dipeptidyl peptidase 4 transgenic mice infected with Middle East respiratory syndrome-coronavirus. PLoS ONE 10, e0145561 (2015).
15. Zhao, J. et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc. Natl Acad. Sci. USA 111, 4970-4975 (2014).
16. Lambeir, A. M., Durinx, C., Scharpe, S. & de Meester, I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit. Rev. Clin. Lab. Sci. 40, 209-294 (2003).
17. Menachery, V. D., Gralinski, L. E., Baric, R. S. & Ferris, M. T. New metrics for evaluating viral respiratory pathogenesis. PLoS ONE 10, e0131451 (2015).
18. Ng, D. L. et al. Clinicopathologic, immunohistochemical, and ultrastructural findings of a fatal case of Middle East respiratory syndrome coronavirus infection in the United Arab Emirates, April 2014. Am. J. Pathol. 186, 652-658 (2016).
19. Tang, X. C. et al. Identification of human neutralizing antibodies against MERSCoV and their role in virus adaptive evolution. Proc. Natl Acad. Sci. USA 111, E2018-E2026 (2014).
20. Agnihothram, S. et al. A mouse model for Betacoronavirus subgroup 2c using a bat coronavirus strain HKU5 variant. mBio 5, e00047-14 (2014).
21. Korteweg, C. & Gu, J. Pathology, molecular biology, and pathogenesis of avian influenza A (H5N1) infection in humans. Am. J. Pathol. 172, 1155-1170 (2008).
22. Ng, W.-F., To, K.-F., Lam, W. W., Ng, T.-K. & Lee, K.-C. The comparative pathology of severe acute respiratory syndrome and avian influenza A subtype H5N1 - a review. Hum. Pathol. 37, 381-390 (2006).
23. Sanders, C. J. et al. Compromised respiratory function in lethal influenza infection is characterized by the depletion of type I alveolar epithelial cells beyond threshold levels. Am. J. Physiol. Lung Cell. Mol. Physiol. 304, L481-L488 (2013).
24. Pascal, K. E. et al. Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection. Proc. Natl Acad. Sci. USA 112, 8738-8743 (2015).
25. Frieman, M. et al. Molecular determinants of severe acute respiratory syndrome coronavirus pathogenesis and virulence in young and aged mouse models of human disease. J. Virol. 86, 884-897 (2012).
26. Thornbrough, J. M. et al. Middle East respiratory syndrome coronavirus NS4b protein inhibits host RNase L activation. mBio 7, e00258 (2016).
27. Dediego, M. L. et al. Pathogenicity of severe acute respiratory coronavirus deletion mutants in hACE-2 transgenic mice. Virology 376, 379-389 (2008).
28. Sims, A. C. et al. Release of severe acute respiratory syndrome coronavirus nuclear import block enhances host transcription in human lung cells. J. Virol. 87, 3885-3902 (2013).
29. Agrawal, A. S. et al. Passive transfer of a germline-like neutralizing human monoclonal antibody protects transgenic mice against lethal Middle East respiratory syndrome coronavirus infection. Sci. Rep. 6, 31629 (2016).
30. Laksitorini, M., Prasasty, V. D., Kiptoo, P. K. & Siahaan, T. J. Pathways and progress in improving drug delivery through the intestinal mucosa and blood- brain barriers. Ther. Deliv. 5, 1143-1163 (2014).
31. McCray, P. B. Jr et al. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J. Virol. 81, 813-821 (2007).
32. Lamers, M. M. et al. Deletion variants of Middle East respiratory syndrome coronavirus from humans, Jordan, 2015. Emerg. Infect. Dis. 22, 716-719 (2016).
33. Scobey, T. et al. Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirus. Proc. Natl Acad. Sci. USA 110, 16157-16162 (2013).
34. Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823-826 (2013).
35. Menachery, V. D. et al. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat. Med. 21, 1508-1513 (2015).
36. Ayala, J. E. et al. Standard operating procedures for describing and performing metabolic tests of glucose homeostasis in mice. Dis. Model. Mech. 3, 525-534 (2010).
37. US Government Deliberative Process Research Funding Pause on Selected Gain-of- Function Research Involving Influenza, MERS, and SARSViruses (USGovernment, 2014); http://www.phe.gov/s3/dualuse/Documents/gain-of-function.pdf